The deal was announced via press release on December 23, 2025, with commercialization expected after regulatory approvals in late 2026 or early 2027, following patent expiry in most markets by March 2026
If you have commercial insurance that does not cover Zepbound, the $25 tier is out of reach, but the card carries a second tier: the KwikPen from $299 per fill, up to 11 fills per calendar year
We used to say that, oh my god, if you lift more than 20 pounds, you're going to explode and die, right
Which is better for weight loss: Zepbound or Mounjaro
Outcome of carbon dioxide laser therapy for persistent cutaneous viral warts
Adding a GLP-1 receptor agonist to the picture strengthens the rationale for the transdermal route